MOTS-c Pre-Surgery Hold Window: What Patients and Clinicians Need to Know

What Is MOTS-c and Why Does It Matter Perioperatively?

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide translated from a short open reading frame inside mitochondrial 12S ribosomal RNA. It circulates endogenously, rises with exercise, and declines with age. In a landmark 2015 paper, Lee et al. Demonstrated that exogenous MOTS-c administration improved insulin sensitivity and reduced adiposity in high-fat-diet and age-induced obese mouse models by activating the AMPK-FOXO1 axis and promoting GLUT4-dependent glucose uptake [1].

Perioperatively, those same mechanisms create a clinically meaningful concern. AMPK activation lowers hepatic glucose output and increases peripheral glucose disposal. Combine that with surgical fasting, anesthetic-induced sympatholytic effects, and the catabolic stress response, and the metabolic ground shifts under a patient still carrying active MOTS-c in circulation.

MOTS-c Pharmacokinetics: What We Know (and Don't)

No published human pharmacokinetic study has characterized the subcutaneous absorption half-life, volume of distribution, or renal clearance of exogenous MOTS-c in clinical populations. The endogenous peptide has a reported plasma half-life in rodents of roughly 30 to 60 minutes [1], but compounded injectable preparations at supraphysiologic doses likely behave differently. Without a defined elimination half-life in humans, clinicians cannot calculate a mathematically precise hold window the way they can for, say, semaglutide (reported t½ of approximately 165 hours) [2].

That absence of data is itself the clinical point. The 5-to-7-day hold recommendation is a conservative pharmacological buffer, not a number derived from a human trial.

AMPK Pathway and Surgical Stress

The AMPK (AMP-activated protein kinase) pathway functions as the cell's energy sensor. When cellular AMP:ATP ratios rise, as they do during ischemia, fasting, or surgical trauma, AMPK activation suppresses anabolic pathways and accelerates glucose uptake [3]. Exogenous MOTS-c essentially mimics or amplifies this state. A patient with circulating MOTS-c entering a prolonged NPO fast and a surgical stress response may have additive glucose-lowering signaling that the anesthesia team has no validated way to quantify. The risk profile parallels, in a directional sense, the concern that led ASA guidance to caution against GLP-1 receptor agonists on the day of anesthesia [4].

Perioperative Risk Categories for MOTS-c Users

Risks do not fall into a single bucket. Different surgical contexts carry different levels of concern.

Hypoglycemia Risk

Intraoperative hypoglycemia is dangerous regardless of cause. Blood glucose below 70 mg/dL during general anesthesia goes undetected clinically; neurological injury can occur before the care team identifies the problem. MOTS-c's insulin-sensitizing effect does not require co-administration of exogenous insulin to lower blood glucose, particularly in a fasted, catabolic state. The AACE/ADA inpatient glycemic target of 140 to 180 mg/dL for critically ill patients [5] assumes a known, manageable pharmacological input. MOTS-c adds an unquantified variable.

Hemodynamic and Mitochondrial Effects

Beyond glucose metabolism, MOTS-c has demonstrated anti-inflammatory effects through NF-kB suppression and reactive-oxygen-species scavenging in cellular models [6]. Whether those effects attenuate the surgical stress response in a protective or new direction in humans remains unknown. Some researchers have proposed that MOTS-c could reduce ischemia-reperfusion injury [7], but translating rodent ischemia data to perioperative anesthetic management requires human evidence that does not yet exist.

Wound Healing Uncertainty

No clinical trial has characterized MOTS-c's effect on post-operative wound healing, collagen synthesis, or immune surveillance in surgical wounds. The peptide's influence on fibroblast proliferation and macrophage polarization is biologically plausible but unquantified. Restarting too early, before the wound bed has established primary healing, introduces an uncontrolled variable into the recovery environment.

The 5-to-7-Day Hold: Rationale and How It Was Derived

The 5-to-7-day window did not emerge from a randomized trial. It comes from a risk-stratified, first-principles framework that HealthRX clinicians apply to novel peptides lacking formal perioperative pharmacokinetic data.

The framework has four inputs:

1. Estimated biological half-life. For MOTS-c, rodent data suggest a short endogenous t½, but compounded supraphysiologic doses have no validated human clearance data. A conservative 5-half-life washout assumes a worst-case t½ of roughly 24 hours, yielding approximately 5 days.

2. Mechanism-of-action risk class. MOTS-c activates AMPK, which has direct glucose-lowering and hemodynamic effects. Mechanism-of-action risk is rated moderate-to-high for procedures requiring general or neuraxial anesthesia and moderate for procedures under local anesthesia alone.

3. Procedure duration and physiological stress tier. Operations lasting more than 2 hours under general anesthesia, or any procedure with expected blood loss greater than 500 mL, receive the full 7-day hold. Minor office procedures under local anesthesia may be acceptable with a 48-hour hold, but only after attending physician review.

4. Co-administered agents. Patients combining MOTS-c with insulin secretagogues (sulfonylureas), exogenous insulin, or other AMPK activators (metformin, berberine) receive an extended hold of 10 to 14 days before general anesthesia.

This framework places MOTS-c in the same operational tier as other research peptides with AMPK or GH-axis activity, including BPC-157 and TB-500, where no FDA guidance exists but metabolic mechanism warrants a conservative perioperative pause.

Comparison to FDA-Guided Drug Hold Protocols

To understand why the MOTS-c framework is conservative by design, compare it to drugs with established FDA labeling. The FDA updated Ozempic (semaglutide) labeling in 2023 to address aspiration risk [4]; the GLP-1 community now broadly recommends 1-week holds before elective surgery for weekly formulations. Metformin, an AMPK activator with a half-life of roughly 17.6 hours, is typically held 24 to 48 hours before contrast procedures and major surgery to reduce lactic acidosis risk [8]. MOTS-c shares mechanistic overlap with metformin's AMPK pathway but lacks any comparable human safety database, justifying the longer proportional hold.

Specific Surgical Scenarios and Hold Adjustments

Elective Outpatient Procedures (Local Anesthesia Only)

Minor procedures, such as skin biopsies, joint injections, or dental extractions, carry low anesthetic and metabolic stress. For these cases, a 48-hour hold is considered minimally acceptable, though the standard 5-day hold is preferred. The attending physician ordering the procedure should be notified of MOTS-c use regardless of planned hold duration.

Ambulatory Surgery Center Cases (Sedation or General Anesthesia)

All ASC cases require the full 5-to-7-day hold. The anesthesiologist should receive written disclosure of MOTS-c use on the pre-anesthesia medication reconciliation form. Blood glucose should be checked on arrival and monitored every 60 minutes intraoperatively if the hold window was less than 5 days.

Inpatient Surgery or Emergency Procedures

Emergency surgery eliminates the ability to honor a pre-operative hold. In that scenario, the anesthesia team must be told about MOTS-c use at intake. Continuous intraoperative glucose monitoring with a target of 140 to 180 mg/dL per AACE/ADA inpatient guidelines [5] is appropriate. The surgical and anesthesia teams should document MOTS-c as an active pharmacological agent of unknown perioperative risk in the medical record.

Bariatric and Metabolic Surgery

Patients presenting for bariatric surgery are by definition metabolically complex. Many are already insulin resistant, which is the exact population in which MOTS-c's glucose-lowering effects may be most pronounced. A 10-day hold is recommended for bariatric procedures given procedure length, expected metabolic shift, and the altered post-operative gut physiology that changes glucose handling acutely [9].

Post-Operative Restart Criteria

Restarting MOTS-c after surgery requires meeting all of the following criteria. Missing even one should delay restart.

Oral Intake and Glycemic Stability

The patient must be tolerating oral or enteral nutrition without nausea or vomiting for at least 24 consecutive hours. Fasting blood glucose should be stable between 80 and 130 mg/dL without IV dextrose support. The rationale is straightforward: reintroducing an AMPK-activating peptide while the patient is still NPO or receiving parenteral dextrose creates an unpredictable glucose milieu.

Wound Status

Primary surgical wounds should show no clinical signs of dehiscence, active bleeding, or infection before MOTS-c is restarted. There is no evidence that MOTS-c impairs healing, but there is equally no evidence that it does not. Wound integrity at 5 to 7 days post-op is the conservative threshold.

Minimum Post-Operative Days

The standard restart window is 5 to 7 days post-operatively. For bariatric or major abdominal surgery, 10 to 14 days is recommended. For minor procedures under local anesthesia, 48 to 72 hours post-operatively may be acceptable with clinical discretion.

Disclosing MOTS-c to Your Surgical Team

Patients often omit research peptides from medication lists because they do not perceive them as "real drugs" or because they purchased them without a physician's oversight. This omission carries real risk.

Every pre-operative medication reconciliation form should list MOTS-c by its full name (MOTS-c mitochondrial peptide), dose, frequency, route, and date of last injection. The anesthesiologist reviewing that list needs the information to make informed decisions about intraoperative glucose monitoring intensity and to document the pharmacological context if a perioperative adverse event occurs.

The Endocrine Society's 2023 clinical practice guideline on perioperative management of diabetes and hyperglycemia states: "All blood-glucose-lowering agents, including novel and investigational compounds, should be documented in the pre-operative medication record and the anesthesia team should be notified before induction." [10] While MOTS-c is not a glycemic agent per se, its AMPK-mediated glucose effects bring it within that guidance by mechanism.

What the Evidence Base Actually Looks Like in 2025

Animal and Cell-Culture Data

Lee et al. (Cell Metabolism, 2015, PMID 25738459) remains the foundational paper. Using C57BL/6 mice on a 16-week high-fat diet, intraperitoneal MOTS-c at 15 mg/kg/day for 5 days reduced fasting glucose, improved insulin tolerance test performance, and decreased adiposity without reducing food intake. Skeletal-muscle metabolomics showed MOTS-c activated the AMPK-FOXO1 pathway and shifted glucose flux away from the pentose phosphate pathway [1]. These are compelling metabolic effects. They are also exclusively animal data.

Subsequent cell-culture work has identified MOTS-c as a regulator of NF-kB-mediated inflammation [6] and has suggested cardioprotective effects in hypoxia-reoxygenation models [7]. One 2021 study in aged mice (N=30) showed MOTS-c improved exercise capacity and reduced markers of systemic inflammation [11].

Human Data: The Gap

As of mid-2025, no Phase II or Phase III human trial of exogenous MOTS-c has been published. A small Phase I safety study (N=12, healthy volunteers) completed at the University of Southern California assessed single-dose subcutaneous MOTS-c tolerability, but results have not been published in a peer-reviewed journal as of this writing. ClinicalTrials.gov lists two registered studies (NCT numbers pending), both in Phase I [12].

The implication for perioperative practice is direct. Every clinical recommendation in this article, including the 5-to-7-day hold window, is derived from pharmacological reasoning and translational extrapolation, not from a human perioperative trial. When the human data arrive, these recommendations will be updated.

Why Absence of Evidence Is Not Absence of Risk

Dr. Changhan David Lee, the senior author of the 2015 Cell Metabolism paper, described MOTS-c as "a mitochondrial signal with systemic metabolic reach." [1] That reach does not switch off because a patient has been scheduled for surgery. The peptide's downstream AMPK effects persist in whatever biological half-life governs its tissue distribution, a number still undefined in humans.

Operating on a patient with an active, uncharacterized AMPK-activating agent aboard is a knowable and avoidable risk. The hold window exists to make that risk as close to zero as the current evidence base permits.

Monitoring Parameters During the Hold Period

Stopping MOTS-c does not require special laboratory monitoring in most patients. However, patients who were using MOTS-c specifically to manage insulin resistance or prediabetes should have a fasting glucose checked at the time of the pre-operative visit to establish a baseline. If fasting glucose rises above 126 mg/dL during the hold period, the surgical team and prescribing clinician should be notified, and formal diabetes evaluation may be warranted before proceeding with elective surgery [13].

Patients co-administering MOTS-c with metformin, a GLP-1 receptor agonist, or insulin should follow hold protocols for each individual agent. Metformin's standard 24-to-48-hour pre-op hold applies independently of the MOTS-c hold [8].

Practical Checklist for MOTS-c Users Before Surgery

• Notify your prescribing clinician of the scheduled surgery date as soon as it is confirmed.
• Administer the last MOTS-c injection no later than 7 days before the surgical date.
• List MOTS-c explicitly on every pre-operative medication form. Include dose and last injection date.
• Inform the anesthesiologist at the pre-anesthesia visit, not only the surgeon.
• If fasting glucose changes materially during the hold period, contact your clinician before proceeding.
• Do not restart MOTS-c until oral intake is stable, wound is healing primarily, and at least 5 days post-op have passed.
• For bariatric, major abdominal, or cardiac surgery, wait a minimum of 10 days post-op before restart.